GTHR GeneThera Inc (CE)

GeneThera, Inc. (PINKSHEETS: GTHR) announced today its new logo and company branding symbol. This new logo represents the shift from a company focused on R&D to Revenue Production and feels the core consumer base will easily identify GeneThera, Inc. The logo will be integrated into the company's packaging and branded materials.

GeneThera will begin to promote the new look to consumers and the public initially through its website and all forms of company media. The company utilized the services of crowdSPRING, which is based in Chicago, IL for the design of the logo. The logo can be found at: http://i679.photobucket.com/albums/vv153/goldsmithgroupllc/genetheralogo.jpg

"We have awarded our packaging contract to the Stephen Gould Corporation," noted Tony Milici. "The firm will incorporate the new logo into the packaging for our HerdGuard(TM) Johne's disease test. The first packaged HerdGuard(TM) products are expected be delivered in February."

The company is working with several distributors to begin fulfilling orders and will update our shareholders on the initial sales results as they are generated.

ABOUT STEPHEN GOULD CORPORATION

The company provides a full range of packaging-related printing services for customers worldwide. Its products include gift packaging, point-of-purchase displays, product merchandising, and retail and industrial packaging. Stephen Gould also provides graphic design and package-engineering services, as well as assembly and fulfillment. Stephen Gould operates from more than 35 facilities. Stephen Gould operates primarily in the US in California, Ohio, and Florida, but the company also runs facilities in China, Ireland, Malaysia, and Mexico. The company was founded in 1939 and is headquartered in Whippany, NJ. The company's website is http://www.stephengould.com.

ABOUT GENETHERA, INC.

GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, Colorado. The Company's proprietary diagnostic solution is based on a genetic expression assay, GES(TM), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES is designed for a host of individual diseases, the current priorities being Mad Cow disease, E. coli 0157:H7 and Johne's disease. For more information, contact Dr. Tony Milici at 303-463-6371 or Al Goldsmith of The Goldsmith Group LLC at 303-838-4370.

This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

Dr. Tony Milici 303-463-6371 Goldsmith Group 303-838-4370 JR Dopkin & Associates 516-884-3200